Teva Pharmaceutical Industries Limited (TEVA): What’s Inside the Story?

uspostnews | April 29, 2019

Teva Pharmaceutical Industries Limited (TEVA): What’s Inside the Story?
On Friday, shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) marked $15.36 per share versus a previous $15.14 closing price. With having a 1.45% gain, an insight into the fundamental values of Teva Pharmaceutical Industries Limited, investors would also find a great ally in the technical patterns of the stock movements showed in stock charts. TEVA showed a fall of -0.39% within its YTD performance, with highs and lows between $14.04 – $25.96 during the period of 52 weeks, compared to the simple moving average of -22.72% in the period of the last 200 days. SunTrust equity researchers changed the status of Teva Pharmaceutical Industries Limited (NYSE: TEVA) shares to a “Hold” rating in the report published on March 20th, 2019. Other analysts, including UBS, also published their reports on TEVA shares. UBS repeated the rating from the previous report, marking TEVA under “Buy” rating, in the report published on March 7th, 2019. Additionally, TEVA shares got another “Equal-Weight” rating from Morgan Stanley, setting a target price of $17 on the company’s shares, according to the report published in March 6th, 2019. On February 20th, 2019, Mizuho Downgrade an Neutral rating and increased its price target from $25 to $18. On the other hand, Raymond James Upgrade the “Outperform” rating for TEVA shares, as published in the report on February 14th, 2019. UBS seems to be going bullish on the price of TEVA shares, based on the price prediction for TEVA. Another “Neutral” rating came from Piper Jaffray.

Spotlight

15 minutes. That’s how long your doctor has to see you, assess your complaint, diagnose a solution and see you out the door hopefully on the pathway back to wellness. This isn’t much time when you consider the wealth of information that he or she has to consider. Your patient record, the medical research relevant to your complaint, the answers about your condition that you provide, the basic examination that is carried out.

Spotlight

15 minutes. That’s how long your doctor has to see you, assess your complaint, diagnose a solution and see you out the door hopefully on the pathway back to wellness. This isn’t much time when you consider the wealth of information that he or she has to consider. Your patient record, the medical research relevant to your complaint, the answers about your condition that you provide, the basic examination that is carried out.

Related News

New AMR Action Fund steps in to save collapsing antibiotic pipeline with pharmaceutical industry investment of US$1 billion

AMR Action Fund | July 09, 2020

Today, more than 20 leading biopharmaceutical companies announced the launch of the AMR Action Fund, a ground-breaking partnership that aims to bring 2-4 new antibiotics to patients by 2030. These treatments are urgently needed to address the rapid rise of antibiotic-resistant infections – also called antimicrobial resistance, or AMR. The companies have raised so far nearly US$1 billion new funding to support clinical research of innovative new antibiotics that are addressing the most resistant bacteria and life-threatening infections. Through the AMR Action Fund, pharmaceutical companies will join forces with philanthropies, development banks, and multilateral organizations to strengthen and accelerate antibiotic development. The Fund will focus on urgent public health needs. It will provide much needed financial resources, as well as important technical support to help biotech companies bring novel antibiotics to patients. The AMR Action Fund, an initiative of the international body representing the R&D pharmaceutical industry (International Federation of Pharmaceutical Manufacturers & Associations, IFPMA), was announced at simultaneous virtual launch events in Berlin, Germany, and Washington, D.C., USA, with a third event in Tokyo, Japan taking place on July 10.

Read More

Lantern Pharma’s Proprietary A.I. Platform Surpasses 450 Million Data Points Accelerating Oncology Drug Development and Drug Response Prediction

Lantern Pharma | June 30, 2020

Lantern Pharma, a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from its targeted oncology therapies, announced today that it surpassed the milestone of 450 million curated data points being utilized in its proprietary A.I. and machine learning-powered platform, RADR® (Response Algorithm for Drug Positioning and Rescue). RADR® leverages genomic, transcriptomic, clinical and drug sensitivity data points across more than 145 drug-tumor interactions to predict the potential response cancer patients will have to potential drugs, therefore enabling a more personalized approach to therapy that is aimed at better outcomes. Lantern is establishing collaborations and partnerships to expand the functionality of RADR®, including algorithms that can operate 200 to 300 percent faster than its existing algorithms, enabling the company to develop robust gene signatures that can be used to guide patient enrollment in trials and as a companion diagnostic (CDx). During the most recent data enrichment campaign, Lantern focused on significantly increasing the depth and amount of data for: non-small cell lung cancer, ovarian cancer, glioblastoma, and gliomas. Reaching this milestone of over 450 million curated data points for oncology drug development will bring greater precision and speed in helping Lantern with its objective of personalizing oncology therapy with reduced risk and cost.

Read More

PHARMACY MARKET

Ionis and AstraZeneca close deal to develop and commercialize eplontersen

Ionis Pharmaceuticals, Inc. | December 30, 2021

Ionis Pharmaceuticals, Inc. the leader in RNA-targeted therapies, announced the closing of the collaboration agreement with AstraZeneca to develop and commercialize eplontersen, Ionis' investigational antisense medicine for the treatment of transthyretin amyloidosis, following expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Eplontersen, formerly known as IONIS-TTR-LRx, is designed to reduce the production of transthyretin, or TTR protein, to treat ATTR, a systemic, progressive and fatal disease. It uses Ionis' advanced LIgand-Conjugated Antisense technology. As previously announced, the companies will jointly develop and commercialize eplontersen in the U.S. AstraZeneca has an exclusive license for eplontersen outside the U.S., except certain countries in Latin America. Under the terms of the agreement, Ionis will receive a $200 million upfront payment, up to $485 million in development and approval milestones, and up to $2.9 billion in sales-related milestone payments. The collaboration includes territory-specific development, commercial and medical affairs cost-sharing provisions. Ionis is also eligible to earn royalties in the range of low double-digit to mid-20s percentage depending on region. Additional details about the agreement can be found in Ionis' Form 8-K filed with the Securities and Exchange Commission on Dec. 7, 2021. About Ionis Pharmaceuticals, Inc. For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading neurological and cardiometabolic franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming one of the most successful biotechnology companies.

Read More